LIMITED PASSES REMAINING

7th Annual

CB1, CB2 & Cannabinoid Drug Development Summit

Translating Novel Preclinical Research Into the Clinic

November 18-20, 2024 | Boston, MA

Accelerating Novel Cannabinoid & Endocannabinoid System (ECS)-Targeting Drugs Approvals in CNS, Obesity & Inflammation

Your 20+ Expert Speakers Include:

Andrea Small Howard
Chief Executive Officer & Chairman of the Board
GB Sciences

Dean Petkanas
Chief Executive Officer
Neuropathix

Parveen Bhatarah
Founder
Medcann

Joe Foss
Founder & Chief Medical Officer
NeuroTherapia

Alexandros Makriyannis
Behrakis Chair of Pharmaceutical Biotechnology
Northeastern University

Mary Ellen Johnson
Global Director Business Development
dsm-firmenich

Proud to Partner With:

BRAINS BIO · dsm-firmenich · FINNEGAN · TRIVERITY LABORATORIES

+1 617 455 4188 info@hansonwade.com
www.cannabinoid-derived-drug-development.com

hansonwade

Discover Novel CB1, CB2 & Cannabinoid Candidates & Overcome Translation Challenges with Targeting Obesity, Pain, CNS & Inflammation

7th Annual CB1, CB2 & Cannabinoid Drug Development Summit

November 18-20, 2024 | Boston, MA

Given the successes of Epidiolex, Marinol, Syndros, and Cesamet, cannabinoid drug developers are evolving drug delivery technologies while exploring novel cannabinoid drug candidates. Meanwhile, major pharmaceutical companies like Novo Nordisk and Roche are showing significant interest in CB1 and CB2 targeting therapies, highlighting their potential in addressing conditions such as weight loss, pain, and neurological disorders. This summit will bring together industry leaders and researchers to share insights and accelerate the development of cannabinoid and ECS-targeting drugs into mainstream treatments for unmet medical needs.

The Industry-focused 7th CB1, CB2 & Cannabinoid Drug Development Summit returns to Boston in November with:

- **Accelerating research impact** with innovative content that highlights the latest momentum in cannabinoid and ECS-targeting R&D
- **Advancing novel targets and modalities** by addressing the unique challenges in cannabinoid drug development
- **Streamlining regulatory pathways** by gaining clarity on the latest approval strategies and cannabinoid regulatory frameworks
- **Learn from recent case studies** to refine your drug delivery systems and research strategies
- **Enhance the efficacy and safety** of your ECS-targeting drugs by optimizing clinical trial design

Join **60+ Discovery**, **Preclinical**, **Translational**, **Regulatory**, **Clinical** and **Chemistry** experts as they seek to ultimately unlock the potential of prescription CB1, CB2 and cannabinoid drugs across obesity, pain, inflammation, CNS and rare diseases.

What's new this year?

- **Uncover** the potential of CB1-targeting therapies for obesity and diabetes treatment options to revolutionize treatment options with the **NIAAA**
- **Harness** the power of AI in plant-based drug discovery and refining precision medicine to enhance outcomes for patient-centric care with **GB Sciences**
- **Maximize on** the capability of the CB2 receptor as a therapeutic target for anti-inflammatory treatments with **Roche**
- **Explore** the potential of controllable CBD-THC mixtures for the treatment of chronic pain with **C-Click Life Sciences**
- **Navigate** the evolving regulatory demands of the cannabinoid drug development market with **Medcann**

5 BENEFITS OF ATTENDING:

1. **Enhance** your knowledge of the endocannabinoid system and CB1 and CB2 maximize on the opportunity for patient populations with improved safety profiles

2. **Gain** preclinical and clinical insights in treating obesity, pain, inflammation and CNS disorders to back translate into your early R&D

3. **Overcome** the challenges associated with API consistency and quality in relation to dosage and bioavailability to gain confidence in your prescription drug candidate

4. **Address** regulatory challenges and achieve compliance with evolving cannabinoid drug development guidelines to demonstrate safety and efficacy with robust in vivo and clinical data

5. **Navigate** the complexities of clinical trial design, including placebo and endpoint strategies, to reduce error, optimally measure efficacy and ensure patient adherence

+1 617 455 4188 info@hansonwade.com
www.cannabinoid-derived-drug-development.com

hansonwade

Your 20+ Expert Speakers

Andrea Small Howard
Chief Executive Officer & Chairman of the Board
GB Sciences

Andrea Chicca
Co-Founder & Chief Executive Officer
Synendos Therapeutics

Alexandros Makriyannis
Behrakis Chair of Pharmaceutical Biotechnology
Northeastern University

Arnold Lippa
Executive Chairman & Chief Scientific Officer
RespireRx Pharmaceuticals



Akeem Gardner
Chief Executive Officer
Canurta

Dean Petkanas
Chief Executive Officer
Neuropathix

Hunter Land
Vice President, Research & Development
Biopharmaceutical Research Co.

Jacci Bainbridge
Professor, Vice Chair, Department of Clinical Pharmacy
Anschutz Outpatient Pavilion, University of Colorado Denver

Joe Foss
Founder & Chief Medical Officer
NeuroTherapia

Jeff Margolis
Senior Vice President & Chief Financial Officer
RespireRx Pharmaceuticals

Kamal Abdur-Rashid
Co-Founder, President & Chief Technology Officer
Kare Chemical Technologies

Michael Palfreyman
Chairman of the Board
C-Click Life Sciences

Parveen Bhatarah
Founder
Medcann

Paul Gavin
Chief Executive Officer
Avecho Biotechnology

Saoirse O'Sullivan
Vice President of Translational Sciences
Artelo Biosciences

Uwe Grether
Expert Scientist & Project Leader Medicinal Chemistry
Roche

Jennifer Triemstra
Associate Medical Director, Cannabinoid Education
Jazz Pharmaceuticals

Heather Krug
Regulatory Programs Branch Chief
Colorado Department of Public Health and Environment (CDPHE)

Mary Ellen Johnson
Global Director Business Development
dsm-firmenich

John Redman
Executive Director
Community Alliances for Drug Free Youth

Terry O'Regan
President
Brains Bioceutical Corp

Matthew Roberts
Chief Operational Officer
FloraWorks



Mehdi Haghdoost
Director of Medicinal Chemistry
Nalu Bio

Pre-Conference Workshop Day
Monday, November 18

Check In & Morning Refreshments 8.00

Workshop A 9.00 - 12.00

Exploring Phytocannabinoids as Drug Candidates: Case Studies for Sleep, Pain, and Inflammation

Phytocannabinoids, known for their interaction with cannabinoid receptors (CB1 and CB2) as well as cannabinoid-like receptors (GPR55, GPR18, etc.), show significant promise as therapeutic agents for various health conditions. This workshop delves into the role of phytocannabinoids in modulating sleep, managing pain, and reducing inflammation, with an emphasis on the therapeutic potential of cannabinol (CBN), cannabidiol (CBD), and cannabigerol (CBG). Attendees will gain insights into existing research on these compounds' effects and explore the possibilities of using phytocannabinoid scaffolds to create new chemical entities (NCEs) in drug discovery. This session aims to foster understanding and discussion on the potential health benefits of phytocannabinoids and NCEs derived from phytocannabinoid scaffolds.

Address critical questions, such as:

- What are the current limitations in the efficacy and safety data surrounding phytocannabinoids?
- Which methodologies are most effective for developing novel cannabinoid-based drugs, and what challenges arise in translating preclinical data to clinical success?
- How can we ensure that cannabinoid-based drug development remains targeted and precise to address specific disease states without unintended psychoactive effects?
- How can phytocannabinoid scaffolds be optimized to enhance interaction with cannabinoid and cannabinoid-like receptors for improved therapeutic outcomes?

Workshop Leaders

Matthew Roberts
Chief Operational Officer
FloraWorks



Mehdi Haghdoost
Director of Medicinal Chemistry
Nalu Bio

Lunch & Networking Break 12.00

Workshop B 1.00 - 4.00

Navigating the Complex Regulatory Landscape for Cannabinoid Research: Governance, Policies, & Pathways

From managing chronic pain to treating epilepsy, cannabinoids offer promising avenues for medical breakthroughs. However, their complex legal and regulatory status has created a dynamic landscape that researchers, policymakers, and pharmaceutical companies must navigate.

Join this workshop to discuss the complex regulatory landscape for cannabinoid research, understand the key governance and policy challenges, and explore the pathways for successful drug development.

Address critical questions, such as:

- What is the impact of FDA pathways on cannabinoid drug approval?
- How can researchers and pharmaceutical companies manage regional restrictions, stigma, and differences between synthetic and phytocannabinoids?
- What are the essential considerations for clinical trial design, safety, efficacy, GMP compliance, and product quality?
- How can variations in global regulations be navigated and multinational trials harmonized to ensure consistent data quality and safety standards?

Workshop Leaders

Parveen Bhatarah
Founder
Medcann

Heather Krug
Regulatory Programs Branch Chief
Colorado Department of Public Health and Environment (CDPHE)

John Redman
Executive Director
Community Alliances for Drug Free Youth

Conference Day One
Tuesday, November 19

7:30 **Morning Refreshments & Check In**

8.25 **Chair's Opening Remarks**

UNLOCKING THE POTENTIAL: PRECLINICAL CONSIDERATIONS TO ENHANCE CANNABINOID DELIVERABILTY & SUSTAINABILTY

8.30 **The Potential of Controllable CBD-THC Mixtures for the Treatment of Chronic Pain**

Michael Palfreyman
Chairman of the Board
C-Click Life Sciences

- The ability to precisely control THC/CBD ratio to more accurately target pain symptoms
- Ensuring good manufacturing practice (GMP) of synthetic API for consistent, high quality drug synthesis
- Analyzing the efficiency of this process compared to extraction
- Developing a drug-delivery device to tailor dosage ratios for personalised and patient-centric treatment

Mary Ellen Johnson
Global Director
Business Development
dsm-firmenich

Terry O'Regan
President
Brains Bioceutical Corp

9.00 **Patient-Centric Innovation in Cannabinoid Medicine Development**

9.30 **Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA)**

Arnold Lippa
Chief Scientific Officer
RespireRx Pharmaceuticals

- Looking at Dronabinol's potential to stabilize respiratory patterns and augment upper airway muscles
- Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption
- Enhancing Dronabinol stability and ease of manufacturing to support commercial scale

10.00 **Speed Networking**

Make the most of your unique networking opportunity at the only industry-focused and scientific event for cannabinoid, CB1 and CB2 drug developers. Reconnect with friendly faces and meet brand new R&D scientists and C-Level leaders from new companies joining the space to forge fruitful relationships and ignite potential collaborations.

11.00 **Morning Break & Refreshments**

CB1 UNLEASHED: FROM PRECLINICAL INSIGHTS TO THERAPEUTIC BREAKTHROUGHS

11.30 **Advancing a Neutral Antagonist of the CB1 Receptor in Preclinical Development for Alcohol, Opioid & Cocaine Use Disorders**

Alexandros Makriyannis
Behrakis Chair of Pharmaceutical Biotechnology
Northeastern University

- Looking at how AM6527, a neutral CB1 receptor antagonist, effectively inhibits heroin and cocaine self-administration under progressive-ratio reinforcement schedules in addiction models
- Discussing behavioural effects and tolerance development in preclinical findings
- Analyzing safety profile and future directions, comparing to Rimonabant suggests it may offer a safer alternative for treating substance use disorders

Conference Day One
Tuesday, November 19

Saoirse O'Sullivan
Vice President of Translational Sciences
Artelo Biosciences

12.00 **ART27.13, a Peripherally Restricted CB1 Agonist Under Clinical Investigation Targeting Cancer Anorexia & Cachexia Syndrome (CACS)**

- Exploring the scientific and clinical validation of ART27.13, a dual CB1/CB2 agonist, through Phase 1 results and its progression to the Phase 2a CAReS Trial for treating CACS
- Analyzing the formulation of ART27.13, its unique chemical properties, and the intellectual property supporting its peripheral receptor selectivity
- Assessing the unmet need in cancer anorexia and cachexia syndrome (CACS) and the potential impact of ART27.13 in addressing this gap

12.30 **Lunch & Networking Break & Scientific Poster Session**

This is an informal session to help you connect with your peers in a relaxed atmosphere to continue forging new and beneficial relationships. With an audience of preclinical, translational, and clinical scientists eager to hear the latest advancements in CB1, CB2, and cannabinoid therapeutic development, you will have the opportunity to display a poster presenting your own work and innovations.

NAVIGATING THE REGULATORY LANDSCAPE: POLICIES, OVERSIGHT, GMP & SAFETY FOR CANNABINOID RESEARCH

Parveen Bhatarah
Founder
Medcann

1.30 **Navigating Novel Cannabinoid Regulatory Pathways During Preclinical & Clinical Research**

- What unique challenges does the industry face when complying with regulations related to novel cannabinoids?
- What can we learn from previous cannabinoid drug approvals to aid the acceleration of new approvals?
- How do we address chemical and biological contaminants in cannabinoid products while adhering to regulations?
- What recent advancements of analytical methodology can we take advantage of to comply with regulatory guidelines?
- How do FDA, USP, and ASTM regulations intersect and diverge concerning cannabinoids?

Kamal Abdur-Rashid
Co-Founder, President & Chief Technology Officer
Kare Chemical Technologies

2.00 **Utilizing Catalytic Synthesis to Produce Rare Cannabinoids**

- Latest advancements surrounding high throughput catalytic processes to prepare CBD and THC, as well as the rare cannabinoids CBDV, THCV, CBDP, THCP, CBN, and more
- Ensuring high chemical and chiral purity are identical to their plant-derived counterparts
- Enabling a stable supply chain, cost-effectiveness, and rigorous quality control while maintaining scalability

2.30 **Afternoon Break & Refreshments**

COLLABORATION & EXPLORATION: UNITING FORCES IN CANNABINOID DRUG DEVELOPMENT & EXPANDING THERAPEUTIC TARGETS

Andrea Chicca
Co-Founder & Chief Executive Officer
Synendos Therapeutics

3.30 **Selective Endocannabinoid Re-uptake Inhibitors (SERIs): A New Class of ECS Modulators for Safe & Effective Treatment of Neuropsychiatric Disorders**

- Presenting the mode of action of SERIs to inhibit eCB re-uptake across plasma membranes by targeting a newly identified protein in the ECS
- SERIs represent a new class of ECS modulators characterized by a distinctive pharmacology profile within the ECS
- Showcasing SYT-510, a clinical candidate of the SERI class.

Conference Day One
Tuesday, November 19

4.00 **Panel Discussion: Overcoming Challenges for Pharmaceutical Engagement in R&D for Cannabinoid & Endocannabinoid System Targeting Drug Development**

- How can pharma work with other stakeholders to de-risk investment in cannabinoid drug development?
- What actions can be taken to de-stigmatise cannabinoid drug development across large pharma?
- How have the first few breakthrough regulatory approvals paved the way for more widely accepted cannabinoid drug development within pharma?
- How can emerging technologies and innovative approaches within pharma accelerate the development and commercialization of cannabinoid-based therapeutics?

Dean Petkanas
Chief Executive Officer
Neuropathix

Paul Gavin
Chief Executive Officer
Avecho Biotechnology

Jennifer Triemstra
Associate Medical Director, Cannabinoid Education
Jazz Pharmaceuticals

4.45 **Chair's Closing Remarks**

5.00 **End of Conference Day 1**

"Outstanding speakers, great additional knowledge gained."

Andrew Mulchinski, Associate Clinical Project Manager & Business Development Associate, **Symbio**

"Non-commercial and highly professional. The attendees were all enthusiastic science-based professionals."

William Beckman, Senior Vice President, Clinical Pharmacology, **Gefion Canada**

Conference Day Two
Wednesday, November 20

8.00 **Morning Refreshments**

Andrea Small Howard
Chief Executive Officer
GB Sciences

8.25 **Chair's Opening Remarks**

CANNABINOID & ECS-TARGETING DRUG DEVELOPMENT: DECODING THE UNIQUE CONSIDERATIONS & UTILIZING INNOVATIVE TECHNOLOGIES

Paul Gavin
Chief Executive Officer
Avecho Biotechnology

8.30 **CBD Dosage Forms: Oral, Transdermal & Buccal Transmucosal - Different Mechanisms to Increase Absorption**

- Investigating techniques and outcomes in clinical trials to improve bioavailability and absorption in oral, transdermal, and buccal transmucosal delivery systems
- Evaluating formulation strategies and technologies designed to optimize CBD absorption and onset of action through different routes of administration
- Comparative analysis of patient outcomes and absorption rates in clinical trials for oral, transdermal, and buccal transmucosal CBD products

Andrea Small Howard
Chief Executive Officer
GB Sciences

9.00 **Harnessing the Power of AI in Plant-Based Drug Discovery & Refining Precision Medicine**

- What are the emerging synergistic methods to utilize traditional models and novel AI technologies in plant-based drug discovery?
- How can these combination methods accelerate phytocannabinoid drug development?
- What benefits can we gain from AI in supporting precision medicine and patient-centric care with phytocannabinoid drug development?

Dean Petkanas
Chief Executive Officer
Neuropathix

9.30 **Novel First-In-Class NCE Targeting GPR55, a Pro-Inflammatory Orphan Cannabinoid Receptor**

- Assessing GPR55 as a target for reducing neuroinflammation and neuropathic pain in preclinical studies
- Advancing a GPR55-targeting drug in preclinical development to address chemotherapy-induced peripheral neuropathy, mitigating pain without interfering with cancer treatment, crucial for maintaining patient compliance with chemotherapy regimens
- Demonstrating the significant impact of this novel compound on mitochondrial health and GPR55 signalling, offering potential breakthroughs in treating Parkinson's disease and various cancers

10.00 **Morning Break & Refreshments**

TRANSLATIONAL TRIUMPH: PROGRESSING CANNABINOID CLINICAL RESEARCH & OPTIMIZING TRIAL DESIGN

Hunter Land
Vice President, Research & Development
Biopharmaceutical Research Company

11.00 **Developing a Framework for Scaling Preclinical Findings to Clinical Success in Cannabinoid Drug Development**

- Navigating regulatory pathways for cannabinoid medicines - insights from the development of Epidiolex and Sativex, including botanical drug guidance, fixed dose concentration, and the FDA 505(b)(2) pathway
- Streamlining approval and compliance for minor cannabinoids - strategies for aligning with regulatory guidelines to ensure safety and efficacy, focusing on cannabinoid combination studies (entourage vs non-tourage)
- Discussing updates on recent findings and results from ongoing clinical trials in cannabinoid drug development

Conference Day Two
Wednesday, November 20

11.30 Roundtable Discussion: Evolving Preclinical & Clinical Trial Design for Cannabinoid Drug Development

- Why have there been relatively few approvals to date of cannabinoid and CB1 and CB2 targeting drugs?
- What promising potential of cannabinoids is there beyond their approved use in conditions like multiple sclerosis, neuropathic pain, and obesity?
- How can we choose the right active ingredient, taking into account safety, efficacy, and therapeutic benefits?
- How can we design trials that prioritize patient experience and compliance?
- How can we address trial complications arising from diverse standards of care across different geographical regions?

Moderator Feedback & Audience Debate

Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open wider audience debate.

Jacci Bainbridge
Professor, Vice Chair, Department of Clinical Pharmacy, Anschutz Outpatient Pavilion
University of Colorado Denver

Hunter Land
Vice President, Research & Development
Biopharmaceutical Research Company

12.30 Lunch & Networking Break

CB2 TARGETING & ECS MODULATION: THERAPEUTIC BENEFITS OF TARGETING THE ENDOCANNABINOID SYSTEM

Uwe Grether
Expert Scientist & Project Leader Medicinal Chemistry
Roche

1.30 Realizing the Potential of the CB2 Receptor as a Therapeutic Target for Anti-Inflammatory Treatments

- Profiling CB2R's role in the endocannabinoid system, and understanding the mechanism of action and how this translates to a clinical benefit
- Analyzing recent scientific advancements, including rationalising CB2 receptor structure-function relationships, AI approaches, and enhance ligand design
- Understanding how biased signalling and binding kinetics will improve tailored therapies

Joseph Foss
Founder & Chief Medical Officer
Neurotherapia

2.00 Using a Synthetic CB2-Targeting Compound to Target Neuroinflammation in the Brain, Mitigating Alzheimer's Disease

- Keeping up with the evolving translational models of CB2-targeting compounds
- Understanding the pathways behind CB2-targeting to treat the neurological symptoms of AD through microglial-mediated neuroinflammation
- Preclinical and clinical research of a candidate compound, NTRX-07, that can readily penetrate the brain and modulate microglial activity via the CB2 receptor
- Exploring possible synergistic effects of NTRX-07 with other therapies used in the treatment paradigm

Saoirse O'Sullivan
Vice President of Translational Sciences
Artelo Biosciences

2.30 Fatty Acid Binding Protein (FABP) Modulation as a Novel Therapeutic Strategy

- Reviewing how FABPs, particular FABP5, are intracellular carrier proteins of endocannnabinoids, and inhibiting FABP5 decreases endocannabinoid uptake and increases endocannabinoid levels
- Introduction to ART26.12, the IND-approved lead small molecule FABP5, being developed for pain indications and the involvement of cannabinoid receptor activation in its analgesic effects
- The broader therapeutic utility of inhibiting FABP5 and other FABP isoforms

3.00 Afternoon Break & Refreshments

FUNDING & FUTURE DIRECTIONS: ADVANCING RESEARCH PRIORITIES IN CANNABINOID & ECS-TARGETING DRUG DEVELOPMENT

Jeff Margolis
Senior Vice President & Chief Financial Officer
RespireRx Pharmaceuticals

3.30 Build, Buy, or Partner: What are the Current Trends for Industry Growth & Organizational Expansion in Clinical Cannabinoid Drug Development

- What are the pros and cons of the "Build" approach in clinical cannabinoid drug development?
- How does the "Buy" strategy offer speed to market and access to talent?
- What advantages and challenges are associated with forming partnerships in this field?

Conference Day Two
Wednesday, November 20

Akeem Gardner
Chief Executive Officer & Founder
Canurta

4.00 **Evolving Cannabinoid Drug Development: Next Generation Multi-Target Therapeutics**

- Exploring a complex therapeutic mixture including cannabinoids, terpenes, and other flavonoids to target the neuro-degenerative effects of CNS disorders such as ALS
- Using innovative technologies to identify and extract the required rare polyphenols at high-potencies
- Utilizing artificial intelligence to help screen the cannabis plant for enhanced insight into which components to research

Andrea Small Howard
Chief Executive Officer
GB Sciences

4.30 **Chair's Closing Remarks**

4.35 **End of Conference**

"Really specific topics with specific people and experts in our field. Felt good to speak with people that understand you."

Lucas Medjani, Business Director & Partner, **STH BIOTECH**

"The presenters were very knowledgeable, and the participants were very interactive."

Trevor Castor, President & Chief Executive Officer, **Aphios Corp**

2024 Partners

Lead Partner

BRAINS BIO

dsm-firmenich

Brains Bio is a leading manufacturer of natural and pure active pharmaceutical ingredients (APIs), with a unique suite of licenses and registrations, Brains Bio is strategically positioned to take advantage of the complex regulatory environment, securing its first-mover and product quality advantage. Brains Bio is diversified across the pharmaceutical, medical, and nutraceutical sectors within the rapidly growing cannabinoid market, resulting in a strong and unique value proposition.

www.brainsbioceutical.com

Exhibition Partner

TRIVERITY LABORATORIES

Triverity Laboratories is a specialized cannabinoid testing lab offering comprehensive analytical services with a global reach and personalized service. our team of scientists and compliance professionals delivers tailored solutions designed to address your unique challenges. we ensure reliable analytical testing that is customized to meet the diverse needs of our international clientele at our ISO/IEC 17025:2017 accredited testing lab.

www.triveritylabs.com

Event Partner

FINNEGAN

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Munich, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices European, German, UK, and U.S. IP law. In addition to services related to all aspects of patent, trademark, and copyright law, including counseling, prosecution, licensing, and litigation, Finnegan provides counseling and litigation services in advertising, privacy, and a wide spectrum of additional IP-adjacent commercial matters, including trade secrets, international trade, the Internet, e-commerce, government contracts, antitrust, and unfair competition.

www.finnegan.com

> "Great content, great support team."
>
> **Julia Duchastel**, Segment Lead, **DSM**

GET INVOLVED

Theodore Beeny
Partnerships Director
Tel: +44 2038543702
Email: theodore.beeny@hansonwade.com

Partnership Opportunities

7th Annual CB1, CB2 & Cannabinoid Drug Development Summit
November 18-20, 2024 | Boston, MA

Maximize on the Growing Field of Cannabinoid & Endocannabinoid System Targeting Drug Development

Growing biotech and pharma communities developing cannabinoid and ECS-targeting drugs are seeking partners to overcome challenges in sourcing, procuring, storing, and supplying high-quality APIs. There is also increasing demand for innovative drug delivery techniques and quality clinical trial design and management as these drugs strive for mainstream market acceptance. Showcase your customized systems for FDA-approved formulations, innovative drug delivery solutions, and leading services to support new R&D customers to clinical success.

At the only summit dedicated to progressing preclinical and clinical prescription drug development for cannabinoid and ECS-targeting therapeutics, position your CRO, CDMO, supplier, or consulting services prominently before preclinical, translational, and clinical decision makers and ensure your brand is front of mind as they choose new partners. Whether it's **Manufacturing High Quality APIs & Drug Substances, Enhancing Drug Delivery System Technologies, Leading Preclinical & Clinical Trial Development, Increasing Efficiency & Compliance with GLP & GMP Regulations, or Laboratory Startup/Optimization**, we'll work with you to build a bespoke package to capitalize on this opportunity and exceed your business needs in 2024.

BENEFITS OF PARTNERING

Showcase
your brand to biotech and pharma executives to distinguish yourself from your competitors and be the go-to solution provider for preclinical and clinical drug developers

Connect
with senior-level decision makers and key stakeholders to foster new and existing relationships in the rapidly expanding cannabinoid drug development space

Enhance
your visibility and recognition as a leading cannabinoid service provider, offering valuable partnerships in a demanding market

Understand
current challenges, shortfalls, and opportunities for improvement in CB1 targeting drug development, capitalizing on the recent explosion of CB1 blockers to treat obesity

Contribute
to the rapidly evolving field of CB1 & CB2 targeting for obesity, pain, and CNS disorders, supporting biotechs in developing novel synthetic cannabinoids and overcoming regulatory challenges

SENIORITY OF ATTENDEES*



- C-Level & VP: 37%
- Director: 23%
- Scientist/Academic Researchers: 11%
- Other: 29%

TYPES OF COMPANIES ATTENDING*



*Statistics Taken from 6th Cannabinoid-Derived Drug Development Summit

GET INVOLVED

Theodore Beeny
Partnerships Director
Tel: +44 2038543702
Email: theodore.beeny@hansonwade.com

+1 617 455 4188 info@hansonwade.com
www.cannabinoid-derived-drug-development.com

hansonwade

Ready to Register?

3 Easy Ways to Book

cannabinoid-derived-drug-development.com/take-part/register/

Tel: +1 617 455 4188

Email: info@hansonwade.com

3 REASONS TO ATTEND:

DISCOVER how leading companies are leveraging existing and novel CB1, CB2, and other cannabinoid receptor-targeted therapeutics to **improve patient treatments for obesity, pain, inflammation, and CNS disorders**

NETWORK with scientific professionals to build your understanding of the current challenges, strategies, and solutions specific to **cannabinoid drug development, cannabinoid receptor target validation, and ECS-targeting drug design**

ENGAGE with your community and peers from leading pharma and biotech companies at this meeting to forge lasting connections, complementary collaborations, and share your **bespoke solutions for cannabinoid receptor drug development**

Drug Developer Pricing*	Register & Pay Before November 18	On the Door Price
Conference + 2 Workshops	$3,397 **(Save $100)**	$3,497
Conference + 1 Workshop	$2,948 **(Save $100)**	$3,048
Conference Only	$2,499 **(Save $100)**	$2,599

Academic Pricing	Register & Pay Before November 18	On the Door Price
Conference + 2 Workshops	$2,797 **(Save $100)**	$2,897
Conference + 1 Workshop	$2,448 **(Save $100)**	$2,548
Conference Only	$2,099 **(Save $100)**	$2,199

Solution Provider Pricing	Register & Pay Before November 18	On the Door Price
Conference + 2 Workshops	$4,297 **(Save $100)**	$4,397
Conference + 1 Workshop	$3,748 **(Save $100)**	$3,848
Conference Only	$3,199 **(Save $100)**	$3,299

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

**Please note, this is subject to change at any time without prior notice

Team Discounts

- **10% discount – 3 Attendees**
- **15% discount – 4 Attendees**
- **20% discount – 5 + Attendees**

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Wyndham Boston Beacon Hill
5 Blossom Street, Boston, MA 02114, United States
www.wyndhambeaconhill.com/